Hemophilia B is a blood disorder that affects about 30,000 people in the United States. Individuals with hemophilia B have a deficiency in factor IX, a protein essential for proper blood clotting. This condition is hereditary, leading to the inability to clot blood effectively.. Treatment for hemophilia B involves injecting factor IX into the veins, but this method is costly and time-consuming. Therefore, scientists are exploring alternative treatments for hemophilia B.
A team of British researchers conducted a gene therapy trial using adenovirus FLT180a to increase factor IX levels in the livers of hemophilia B patients. They administered this gene therapy to a total of 10 male patients with severe or moderate hemophilia B, aged between 25 to 67 years. The patients were given different doses of the adenovirus and monitored for 26 weeks.
The results of the trial showed that some patients reached normal factor IX levels, while others experienced dangerously high levels. Patients who received lower doses had factor IX levels ranging from 40% to 60% of normal, while those who received higher doses had levels up to 300% of normal. The researchers noted varying responses in different patients and observed side effects like unexpected bleeding.
Despite the variability in patient response, the researchers believe that gene therapy could be a potential treatment for increasing factor IX levels in hemophilia B patients and improving blood clotting. They caution about the need to monitor and manage side effects effectively and suggest that this therapy could provide benefits for up to a year before requiring further intervention.
Post views: 1,128
Source: sciworthy.com
